Oura S, Tanino H, Yoshimasu T, Sakurai T, Nakamura T, Kokawa Y, Matsuyama K, Naito Y
1st Dept. of Surgery, Wakayama Medical College.
Gan To Kagaku Ryoho. 2001 Apr;28(4):511-4.
A 73-year-old woman underwent docetaxel therapy for lung metastasis from breast cancer after having received CAF therapy. Because of the progressive disease due to secondary resistance to docetaxel, the patient was given three courses of paclitaxel therapy (60 mg/m2, day 1, 8, 15 and 22, repeated every 6 weeks). The paclitaxel therapy brought about no adverse effects and a 51%-reduction in the size of the metastatic lung tumor (PR). Although the duration of the response to the paclitaxel therapy was limited to about one month due to progression of a brain metastasis, paclitaxel therapy may be effective against docetaxel-resistant breast cancer.
一名73岁女性在接受CAF治疗后，因乳腺癌肺转移接受多西他赛治疗。由于对多西他赛继发耐药导致病情进展，该患者接受了三个疗程的紫杉醇治疗（60mg/m²，第1、8、15和22天，每6周重复一次）。紫杉醇治疗未产生不良反应，肺转移瘤大小缩小了51%（部分缓解）。尽管由于脑转移进展，对紫杉醇治疗的反应持续时间限于约一个月，但紫杉醇治疗可能对多西他赛耐药的乳腺癌有效。
